ASCO 2016 - Brystkræft
HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles | Bentham Science
A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status | SpringerLink
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. - Abstract - Europe PMC
The application and prospect of CDK4/6 inhibitors in malignant solid tumors | Journal of Hematology & Oncology | Full Text
Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies
Therapy options after CDK4/6 inhibitors for HR+, HER2- postmenopausal metastatic/recurrent breast cancer in Japan: a role for mammalian target of rapamycin inhibitors? | Future Oncology
A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib - ScienceDirect
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences | SpringerLink
A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib - ScienceDirect
CDK 4/6-hæmmer plus førstelinjebehandling forlænger overlevelsen ved metastaserende brystkræft - Dagens Medicin
Molecules | Free Full-Text | Development of CDK4/6 Inhibitors: A Five Years Update
Ribociclib
The Biological Rationale for CDK4/6 Inhibitors - YouTube
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. - Abstract - Europe PMC
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation - ScienceDirect
Ribociclib
Medicinrådets vurdering vedr. alpelisib i komb. med fulvestrant til metastatisk brystkræft-vers 1.0
CDK4/6 inhibitors: a novel strategy for tumor radiosensitization | Journal of Experimental & Clinical Cancer Research | Full Text
The application and prospect of CDK4/6 inhibitors in malignant solid tumors | Journal of Hematology & Oncology | Full Text
Frontiers | CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
Medicinrådets lægemiddelrek. og beh.vejl. vedr. CDK46-hæmmere til ER+HER2- lokalt fremskreden eller metastatisk brystkræft
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Medicinrådets protokol for vurdering vedr. alpelisib til ER+HER2- brystkræft med PIK3CA-mutation-vers. 1.0
